Denali Therapeutics Inc. 8-K

What Happened
Denali Therapeutics reported on April 3, 2026 that Takeda Pharmaceutical Company Limited gave written notice terminating the Collaboration Agreement dated January 3, 2018, to co-develop and co‑commercialize DNL593 (PTV:PGRN). Takeda said the decision was driven by strategic considerations and was not related to any efficacy or safety data. The termination becomes effective 60 days after the notice date, at which point all rights to the DNL593 program will revert to Denali.

Key Details

• Agreement: Collaboration Agreement between Denali and Takeda dated January 3, 2018.
• Notice date: April 3, 2026; termination effective 60 days after notice (on or about June 2, 2026).
• Program affected: DNL593 (PTV:PGRN) — all rights revert to Denali upon termination.
• Financial impact: Denali will have no further financial obligations to Takeda after termination.

Why It Matters
For investors, this filing means Denali regains full control of the DNL593 program and will no longer share development or commercialization rights with Takeda. The company also avoids further payments or obligations to Takeda under the collaboration. The filing stresses the termination was strategic and not tied to safety or efficacy, which helps clarify the program’s regulatory/clinical status but does not provide new clinical or financial results.